HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities

Aim—To test the hypothesis that, because the human papillomavirus (HPV) E2 protein represses viral early gene transcription, E2 gene sequence variation or disruption could play a part in the induction of the numerical chromosome abnormalities that have been described in squamous cervical lesions. Methods—The integrity and sequence of the E2 gene from 11 cervical intraepithelial neoplasia (CIN) grade 3 lesions and 14 invasive squamous cell carcinomas, all of which contained HPV-16, were analysed by the polymerase chain reaction (PCR). The E2 gene was amplified in three overlapping fragments and PCR products sequenced directly. Chromosome abnormalities were identified by interphase cytogenetics using chromosome specific probes for chromosomes 1, 3, 11, 17, 18, and X. Results—E2 gene disruption was present in significantly more invasive carcinomas (eight of 14) than CIN 3 lesions (one of 11) (p = 0.03). No association was found between E2 disruption and the presence of a numerical chromosome abnormality. The E2 gene from the non-disrupted isolates was sequenced and wild-type (n = 5) and variant (n = 11) sequences identified. Variant sequences belonged to European and African classes and contained from one to 15 amino acid substitutions. Although numerical chromosome abnormalities were significantly more frequent in invasive squamous cell carcinoma than CIN 3 (p = 0.04), there was no significant relation between the presence of sequence variation and either histological diagnosis or chromosome abnormality. Conclusions—These data do not support the hypothesis that E2 gene disruption or variation is important in the induction of chromosome imbalance in these lesions. However, there is a relation between E2 gene disruption and the presence of invasive disease.

[1]  J. Berumen,et al.  Asian‐American variants of human papillomavirus type 16 have extensive mutations in the E2 gene and are highly amplified in cervical carcinomas , 1999, International journal of cancer.

[2]  J. Meissner Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. , 1999, The Journal of general virology.

[3]  C. Wheeler,et al.  Human papillomavirus type 16 variant lineages characterized by nucleotide sequence analysis of the E5 coding segment and the E2 hinge region. , 1999, The Journal of general virology.

[4]  C. Wheeler,et al.  Human papillomavirus type 16 variant lineages characterized by nucleotide sequence analysis of the E 5 coding segment and the E 2 hinge region , 1999 .

[5]  E. Androphy,et al.  Crystal structure of the E2 DNA-binding domain from human papillomavirus type 16: implications for its DNA binding-site selection mechanism. , 1998, Journal of molecular biology.

[6]  R. Holm,et al.  Disruption of the E1 and E2 Reading Frames of HPV 16 in Cervical Carcinoma Is Associated with Poor Prognosis , 1998, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[7]  T. R. Broker,et al.  The Carboxyl-Terminal Region of the Human Papillomavirus Type 16 E1 Protein Determines E2 Protein Specificity during DNA Replication , 1998, Journal of Virology.

[8]  C. Herrington,et al.  Interphase cytogenetic evidence for distinct genetic pathways in the development of squamous neoplasia of the uterine cervix. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[9]  C. Cooper,et al.  Identification of single amino acids in the human papillomavirus 11 E2 protein critical for the transactivation or replication functions. , 1998, Virology.

[10]  C. H. Buckley,et al.  Aetiology, pathogenesis, and pathology of cervical neoplasia. , 1998, Journal of clinical pathology.

[11]  J. Dillner,et al.  Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein. , 1997, The Journal of general virology.

[12]  M. Evans,et al.  Basal cell tetrasomy in low-grade cervical squamous intraepithelial lesions infected with high-risk human papillomaviruses. , 1997, Cancer research.

[13]  C. Meijer,et al.  A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings , 1997, Journal of clinical microbiology.

[14]  C. Wheeler,et al.  Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective , 1997, Journal of virology.

[15]  M. Frattini,et al.  Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein , 1997, The EMBO journal.

[16]  J. Meissner Sequencing Errors in Reference HPV Clones , 1997 .

[17]  F. Wiklund,et al.  Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer , 2006, International journal of cancer.

[18]  P. Howley,et al.  Suppression of cellular proliferation by the papillomavirus E2 protein , 1995, Journal of virology.

[19]  C. M. Sanders,et al.  Characterization of human papillomavirus type 16 E2 protein and subdomains expressed in insect cells. , 1995, Virology.

[20]  L. Banks,et al.  Mutations in the human papillomavirus type 16 E2 protein identify a region of the protein involved in binding to E1 protein. , 1995, The Journal of general virology.

[21]  C. M. Sanders,et al.  Kinetic and equilibrium binding studies of the human papillomavirus type-16 transcription regulatory protein E2 interacting with core enhancer elements. , 1994, Nucleic acids research.

[22]  H. Bernard,et al.  The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID , 1994, Journal of virology.

[23]  J. Underwood Diagnostic Molecular Pathology. A Practical Approach , 1993 .

[24]  T. R. Broker,et al.  Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Howley,et al.  Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Stanley,et al.  Lack of immortalizing activity of a human papillomavirus type 16 variant DNA with a mutation in the E2 gene isolated from normal human cervical keratinocytes. , 1992, Oncogene.

[27]  D. McCance,et al.  Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes , 1992, Journal of virology.

[28]  D. Lowy,et al.  The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture , 1991, Journal of virology.

[29]  J. Dillner,et al.  A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Howley,et al.  Transcriptional trans-activation by the human papillomavirus type 16 E2 gene product , 1987, Journal of virology.

[31]  M. Braun,et al.  Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines , 1987, Journal of virology.

[32]  P. Howley,et al.  Transactivation of a bovine papilloma virus transcriptional regulatory element by the E2 gene product , 1985, Cell.

[33]  P. Howley,et al.  Transcriptional transActivation by the Human Papillomavirus Type 16 E 2 Gene Product , 2022 .